Market Intelligence, Clinical Progress, and High-Purity Reagents for Proteasome Modulator and Targeted Protein Degradation Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for PSMA1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PSMA1 Recombinant Protein (WT & Mutant). High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. Theoretical MW. HEK293 expressed. | View PSMA1 Products |
| Gene Delivery | PSMA1 Promise-ORF / Lentivirus. Full-length ORF for stable cell lines. | View PSMA1 Products |
| Benchmark Ab | Anti-PSMA1 Recombinant Antibody. Sequence-defined positive control for Western/IP. | View PSMA1 Products |
| Validator | PSMA1 siRNA Set. For knockdown and specificity verification. | View PSMA1 Products |
| Catalytic Partner: PSMB5 | PSMB5 (Proteasome 20S Subunit Beta 5). Catalytic subunit targeted by bortezomib/carfilzomib; essential for inhibitor screening. | View PSMB5 Products |
| Alpha-ring Counterpart: PSMA3 | PSMA3. Alpha-ring counterpart for complex assembly and molecular glue specificity. | View PSMA3 Products |
| Immunoproteasome: PSMB8 | PSMB8 (LMP7). Immunoproteasome-specific catalytic subunit; pathway alternative. | View PSMB8 Products |
| Regulatory Complex: PSMD1 | PSMD1 (Proteasome 26S Subunit, Non-ATPase 1). 19S regulatory particle component; required for UPS-mediated degradation assays. | View PSMD1 Products |
Critical Assay Challenges & Technical Specifications
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Alpha-Ring Assembly Verification (Heptameric stoichiometry) | High-purity monomeric PSMA1 (>95% by SEC-HPLC) for oligomerization studies; Theoretical MW 29.6 kDa confirmed by Mass Spec. |
| Gate Opening Mechanism Studies | Native glycosylation-free format (HEK293) ensuring authentic protein-protein interactions for substrate entry assays. |
| Distinguishing constitutive vs. immunoproteasome complexes | Homologous proteasome subunit panel (PSMA1–PSMA7, PSMB5/8/9/10) with sequence-verified identity. |
| Drug Resistance Mutation Screening | Custom PSMA1 Mutant Library available (e.g., N146D, S147A). Includes reported mutation rs17850016 (UniProt VAR_067454) for resistance bypass studies. |
| Off-target binding across alpha-ring subunits | Sequence-defined anti-PSMA1 antibody for paralog discriminating assays. |
| Lack of cellular knockdown controls | Predesigned siRNA included for specificity checks in UPS reporter assays. |
| Cross-species Preclinical Evaluation | Human/Mouse/Rat ortholog proteins available with >95% purity; Endotoxin Controlled (<0.1 EU/µg). |
| Intracellular Target Selectivity | High Purity (>95%) recombinant proteins strictly verified by mass spec for binding assays. |
Live PSMA1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for next-generation proteasome therapeutics is intensifying, with major players shifting focus from broad-spectrum beta-subunit inhibitors to selective immunoproteasome modulators, alpha-subunit allosteric regulators, and specific degraders such as PROTACs and molecular glues. As first-generation proteasome inhibitors (bortezomib, carfilzomib) mature in oncology, the next wave of R&D is targeting compensatory mechanisms and resistance profiles governed by structural subunits like PSMA1. This includes PSMA1-mediated gating mechanisms and 20S particle assembly disruption to achieve tissue-specific inhibition with reduced toxicity. Emerging indications span autoimmune diseases, neurodegenerative proteinopathies, and optimized targeted protein degradation platforms.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors (Beta-subunit) | Takeda, Amgen, Bristol Myers Squibb | Multiple Myeloma, Lymphoma | 20S Reconstitution Assay (Need high-purity PSMA1 for alpha-ring assembly) |
| Immunoproteasome-Selective Inhibitors | Kezar Life Sciences, ONO Pharmaceutical | Autoimmune Diseases, Oncology | Selectivity Assay (Need PSMA1 + immunoproteasome subunit panel) |
| PROTACs / Molecular Glues | Arvinas, Nurix Therapeutics, C4 Therapeutics | Solid Tumors, Hematologic Malignancies | Ternary Complex Validation (Need high-purity PSMA1 for binding assays) |
| Assembly Disruptors (Small Molecule) | Oncology Pipeline Programs | Multiple Myeloma, Solid Tumors | Alpha-Ring Oligomerization Assay (Need monodisperse PSMA1 for accurate kinetic studies) |
| Peptide Therapeutics | Emerging Startups | Solid Tumors | Intracellular Binding Assay (Need native-folded antigens) |
| Neurodegenerative Modulators | Biogen, Academic Labs | Alzheimer's, Parkinson's | Protein Aggregation Protection Assays (Need high-stability PSMA1 mutants) |